Clinical and Radiological Improvement Following a Switch to Upadacitinib in Giant Cell Arteritis with Recurrent Ischemic Strokes During High-Dose Glucocorticoid and Tocilizumab Treatment: A Case Report
Modern Rheumatology Case Reports · 17.11.2026
DOI: 10.1093/mrcr/rxag101 ↗Kurz gefasst
Fallbericht in der Zeitschrift Modern Rheumatology Case Reports, online erschienen am 17.11.2026. Verfasst von Haruka Yonezawa und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Seirei Hamamatsu General Hospital, Hamamatsu, Shizuoka, Japan.
Abstract (Originalsprache)
Giant cell arteritis (GCA) is a systemic rheumatic disease that affects the large vessels. Although ischemic stroke is an uncommon complication of GCA, intracranial vasculitis may lead to recurrent strokes. An 81-year-old man presented with progressive gait disturbance. Physical examination revealed bilateral temporal artery tenderness with markedly diminished pulsation. His serum C-reactive protein level was elevated. Temporal artery ultrasonography demonstrated bilateral halo signs. Brain magnetic resonance imaging revealed multiple acute strokes. Vessel wall imaging demonstrated circumferential wall thickening with contrast enhancement of the bilateral intracranial internal carotid and vertebral arteries. He fulfilled the 2022 ACR/EULAR classification criteria for GCA. Treatment with intravenous methylprednisolone followed by high-dose glucocorticoid (GC) and weekly subcutaneous (SC) tocilizumab (TCZ) was initiated. However, recurrent ischemic strokes occurred early after treatment initiation, accompanied by progression of intracranial arterial stenosis. Therefore, TCZ was subsequently switched to upadacitinib (UPA) 15 mg/day. Following the switch to UPA, the serum C-reactive protein level normalized, no further ischemic strokes occurred, and follow-up contrast-enhanced MRI demonstrated resolution of vascular wall enhancement. This case describes clinical and radiological improvement observed following the switch to UPA in rapidly progressive GCA with intracranial involvement.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Rheumatology, Seirei Hamamatsu General Hospital, Hamamatsu, Shizuoka, Japan.
- Department of Neurology, Seirei Hamamatsu General Hospital, Hamamatsu, Shizuoka, Japan.
ORCID-Profile: Shin-Ichiro Ohmura
Zitieren
APA
Yonezawa, H., Fukami, S., Tomiyama, K., Aoki, T., & Ohmura, S. I. (2026). Clinical and Radiological Improvement Following a Switch to Upadacitinib in Giant Cell Arteritis with Recurrent Ischemic Strokes During High-Dose Glucocorticoid and Tocilizumab Treatment: A Case Report. Modern Rheumatology Case Reports. https://doi.org/10.1093/mrcr/rxag101
Vancouver
Yonezawa H, Fukami S, Tomiyama K, Aoki T, Ohmura SI. Clinical and Radiological Improvement Following a Switch to Upadacitinib in Giant Cell Arteritis with Recurrent Ischemic Strokes During High-Dose Glucocorticoid and Tocilizumab Treatment: A Case Report. Modern Rheumatology Case Reports. 2026. doi:10.1093/mrcr/rxag101
BibTeX
@article{Yonezawa2026,
author = {Yonezawa, Haruka and Fukami, Soma and Tomiyama, Kazuki and Aoki, Tadashi and Ohmura, Shin-Ichiro},
title = {Clinical and Radiological Improvement Following a Switch to Upadacitinib in Giant Cell Arteritis with Recurrent Ischemic Strokes During High-Dose Glucocorticoid and Tocilizumab Treatment: A Case Report},
journal = {Modern Rheumatology Case Reports},
year = {2026},
doi = {10.1093/mrcr/rxag101}
}
EUVIMED